S&P 500   3,346.85 (+0.57%)
DOW   27,364.79 (+0.60%)
QQQ   274.24 (+1.18%)
AAPL   454.48 (+3.23%)
MSFT   215.43 (+1.17%)
FB   265.89 (+6.73%)
GOOGL   1,505.80 (+1.81%)
AMZN   3,232.68 (+0.86%)
NVDA   453.37 (+0.42%)
CGC   17.92 (-6.72%)
BABA   264.55 (-0.14%)
TSLA   1,497.56 (+0.84%)
MU   49.08 (-3.86%)
GE   6.35 (-0.78%)
AMD   86.55 (+1.45%)
T   29.84 (-0.03%)
F   6.96 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.89 (-0.16%)
NFLX   507.83 (+1.14%)
DIS   131.41 (+2.98%)
BAC   25.46 (+0.28%)
BA   172.81 (-0.84%)
S&P 500   3,346.85 (+0.57%)
DOW   27,364.79 (+0.60%)
QQQ   274.24 (+1.18%)
AAPL   454.48 (+3.23%)
MSFT   215.43 (+1.17%)
FB   265.89 (+6.73%)
GOOGL   1,505.80 (+1.81%)
AMZN   3,232.68 (+0.86%)
NVDA   453.37 (+0.42%)
CGC   17.92 (-6.72%)
BABA   264.55 (-0.14%)
TSLA   1,497.56 (+0.84%)
MU   49.08 (-3.86%)
GE   6.35 (-0.78%)
AMD   86.55 (+1.45%)
T   29.84 (-0.03%)
F   6.96 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.89 (-0.16%)
NFLX   507.83 (+1.14%)
DIS   131.41 (+2.98%)
BAC   25.46 (+0.28%)
BA   172.81 (-0.84%)
S&P 500   3,346.85 (+0.57%)
DOW   27,364.79 (+0.60%)
QQQ   274.24 (+1.18%)
AAPL   454.48 (+3.23%)
MSFT   215.43 (+1.17%)
FB   265.89 (+6.73%)
GOOGL   1,505.80 (+1.81%)
AMZN   3,232.68 (+0.86%)
NVDA   453.37 (+0.42%)
CGC   17.92 (-6.72%)
BABA   264.55 (-0.14%)
TSLA   1,497.56 (+0.84%)
MU   49.08 (-3.86%)
GE   6.35 (-0.78%)
AMD   86.55 (+1.45%)
T   29.84 (-0.03%)
F   6.96 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.89 (-0.16%)
NFLX   507.83 (+1.14%)
DIS   131.41 (+2.98%)
BAC   25.46 (+0.28%)
BA   172.81 (-0.84%)
S&P 500   3,346.85 (+0.57%)
DOW   27,364.79 (+0.60%)
QQQ   274.24 (+1.18%)
AAPL   454.48 (+3.23%)
MSFT   215.43 (+1.17%)
FB   265.89 (+6.73%)
GOOGL   1,505.80 (+1.81%)
AMZN   3,232.68 (+0.86%)
NVDA   453.37 (+0.42%)
CGC   17.92 (-6.72%)
BABA   264.55 (-0.14%)
TSLA   1,497.56 (+0.84%)
MU   49.08 (-3.86%)
GE   6.35 (-0.78%)
AMD   86.55 (+1.45%)
T   29.84 (-0.03%)
F   6.96 (-0.29%)
ACB   10.26 (-4.20%)
GILD   68.89 (-0.16%)
NFLX   507.83 (+1.14%)
DIS   131.41 (+2.98%)
BAC   25.46 (+0.28%)
BA   172.81 (-0.84%)
Log in

NASDAQ:ABUSArbutus Biopharma Stock Price, Forecast & News

$4.33
+0.15 (+3.59 %)
(As of 08/6/2020 02:57 PM ET)
Add
Compare
Today's Range
$4.26
Now: $4.33
$4.88
50-Day Range
$1.75
MA: $2.64
$6.20
52-Week Range
$0.82
Now: $4.33
$9.02
Volume343,595 shs
Average Volume22.27 million shs
Market Capitalization$298.60 million
P/E RatioN/A
Dividend YieldN/A
Beta3.25
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. The company develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer AB-452, an orally administered agent, in pre-clinical studies in destabilizing HBV RNA, which leads to RNA degradation and to reduction in HBsAg levels. In addition, it engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with SOC therapies, and in combination with each other. The company has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Acuitas Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Monsanto Company; Marina Biotech, Inc.; and Arcturus Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Read More
Arbutus Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.74 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABUS
CUSIPN/A
Phone267-469-0914

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.01 million
Book Value($1.00) per share

Profitability

Net Income$-153,720,000.00
Net Margins-2,091.92%

Miscellaneous

Employees79
Market Cap$298.60 million
Next Earnings Date8/7/2020 (Confirmed)
OptionableOptionable
$4.33
+0.15 (+3.59 %)
(As of 08/6/2020 02:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

How has Arbutus Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABUS shares have increased by 67.8% and is now trading at $4.33.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Arbutus Biopharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arbutus Biopharma
.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020.
View our earnings forecast for Arbutus Biopharma
.

How can I listen to Arbutus Biopharma's earnings call?

Arbutus Biopharma will be holding an earnings conference call on Friday, August 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) issued its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.06. The biopharmaceutical company had revenue of $1.49 million for the quarter, compared to analysts' expectations of $1.81 million.
View Arbutus Biopharma's earnings history
.

What price target have analysts set for ABUS?

6 brokerages have issued 12-month price objectives for Arbutus Biopharma's shares. Their forecasts range from $4.00 to $8.00. On average, they expect Arbutus Biopharma's share price to reach $5.80 in the next year. This suggests a possible upside of 33.9% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
.

Has Arbutus Biopharma been receiving favorable news coverage?

Media stories about ABUS stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arbutus Biopharma earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Arbutus Biopharma
.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a increase in short interest in July. As of July 31st, there was short interest totaling 765,100 shares, an increase of 19.3% from the July 15th total of 641,200 shares. Based on an average trading volume of 6,720,000 shares, the short-interest ratio is presently 0.1 days. Approximately 1.6% of the company's shares are short sold.
View Arbutus Biopharma's Current Options Chain
.

Who are some of Arbutus Biopharma's key competitors?

What other stocks do shareholders of Arbutus Biopharma own?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:
  • Dr. Mark Joseph Murray, Pres, CEO & Director (Age 70)
  • Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 58)
  • Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 56)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 61)
  • Dr. Elizabeth Howard, Exec. VP, Gen. Counsel & Chief Compliance Officer (Age 65)

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Jennison Associates LLC (0.49%), UBS Group AG (0.47%), Russell Investments Group Ltd. (0.06%) and Creative Planning (0.05%). Company insiders that own Arbutus Biopharma stock include Michael J Mcelhaugh and Michael J Sofia.
View institutional ownership trends for Arbutus Biopharma
.

Which institutional investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Jennison Associates LLC.
View insider buying and selling activity for Arbutus Biopharma
.

Which institutional investors are buying Arbutus Biopharma stock?

ABUS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and Creative Planning.
View insider buying and selling activity for Arbutus Biopharma
.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $4.33.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $298.60 million and generates $6.01 million in revenue each year. The biopharmaceutical company earns $-153,720,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Arbutus Biopharma employs 79 workers across the globe.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at 267-469-0914 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.